CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients (Q2867196): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The project presented by LIMM Therapeutics aims to evaluate the possibility of developing NRIL01 (neurnal reprogrammers of innate lymphocytes) in the presence of SARS-CoV-2, thus contributing to minimising renal pathologies as a consequence of infection with this virus., translated_summary) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients | |||
Revision as of 01:13, 7 July 2021
Project Q2867196 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients |
Project Q2867196 in Portugal |
Statements
492,223.04 Euro
0 references
76.0 percent
0 references
1 April 2020
0 references
31 December 2020
0 references
LIMM THERAPEUTICS, SOCIEDADE ANÓNIMA
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
O projeto apresentado pela LiMM Therapeutics pretende avaliar a possibilidade de desenvolvimento de NRIL01 (reprogramadores neuronais de linfócitos inatos) na presença de SARS-CoV-2, contribuindo desta forma para minimizar as patologias renais como consequência da infeção com este vírus. (Portuguese)
0 references
The project presented by LIMM Therapeutics aims to evaluate the possibility of developing NRIL01 (neurnal reprogrammers of innate lymphocytes) in the presence of SARS-CoV-2, thus contributing to minimising renal pathologies as a consequence of infection with this virus. (English)
7 July 2021
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-02B7-FEDER-069917
0 references